Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

Jänne, Pasi A; Shaw, Alice T; Pereira, José Rodrigues; Jeannin, Gaëlle; Vansteenkiste, Johan; Barrios, Carlos; Franke, Fabio Andre; Grinsted, Lynda; Zazulina, Victoria; Smith, Paul; Smith, Ian; Crinò, Lucio

doi:10.1016/S1470-2045(12)70489-8

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

Author:

Jänne, Pasi A

Shaw, Alice T ; Pereira, José Rodrigues ; Jeannin, Gaëlle ; Vansteenkiste, Johan ; Barrios, Carlos ; Franke, Fabio Andre ; Grinsted, Lynda ; Zazulina, Victoria ; Smith, Paul ; Smith, Ian ; Crinò, Lucio

Keywords:

Adult, Aged, Benzimidazoles, Carcinoma, Non-Small-Cell Lung, Disease-Free Survival, Drug-Related Side Effects and Adverse Reactions, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Prospective Studies, Protein Kinase Inhibitors, Proto-Oncogene Proteins, Taxoids, ras Proteins, Science & Technology, Life Sciences & Biomedicine, Oncology, INHIBITOR AZD6244 ARRY-142886, GROWTH-FACTOR RECEPTOR, OPEN-LABEL, MEK1/2 INHIBITOR, RAS ONCOGENE, III TRIAL, CHEMOTHERAPY, COMBINATION, MUTATIONS, GEFITINIB, Docetaxel, Proto-Oncogene Proteins p21(ras), 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, 3211 Oncology and carcinogenesis

Abstract:

No targeted therapies are available for KRAS-mutant non-small-cell lung cancer (NSCLC). Selumetinib is an inhibitor of MEK1/MEK2, downstream of KRAS, with preclinical evidence of synergistic activity with docetaxel in KRAS-mutant cancers. We did a prospective, randomised, phase 2 trial to assess selumetinib plus docetaxel in previously treated patients with advanced KRAS-mutant NSCLC.